Work

Recombinant Interferon-Beta1a Use in Six Patients with Myeloproliferative Neoplasms: A First Impression

Year: 2025

Type: article

Abstract: Objective: Assess the safety and efficacy of recombinant interferon-beta1a (rIFN-β1a) in myeloproliferative neoplasm (MPN) patients transitioning from pegylated interferon-alpha2 (peg-IFN-α2). Method: Retrospective review of six MPN patients switching to rIFN-β1a (44 mcg weekly). Results: All patients reported myalgia. No other adverse events or treatment discontinuations. Reduced JAK2V617F allele burden in three patients. Conclusion: rIFN-β1a demonstrated manageable safety in MPN patients, with potential efficacy. Larger studies are needed.

Source: DAHUDER Medical Journal

DOI: 10.56016/dahudermj.1647004

Author: Püsem Patır

Institutions: Antalya Eğitim ve Araştırma Hastanesi, Sağlık Bilimleri Üniversitesi

Language: English

Topic: Myeloproliferative Neoplasms: Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

OpenAlex ID: W4410108252

FWCI:

Cites: 7

Cited by:

Related to: 10